Skip to main content
SpringerLink
Log in

Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

To investigate whether integrated fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) can differentiate benign from adrenal malignant lesions on the basis of maximum standardized uptake value (SUVmax), tumor/liver (T/L) SUVmax ratio, and CT attenuation value (Hounsfield Units; HU) of unenhanced CT obtained from FDG-PET/CT data.

Methods

We studied 30 patients with 35 adrenal lesions (16 adrenal benign lesions, size 16 ± 5 mm, in 15 patients; and 19 adrenal malignant lesions, 24 ± 12 mm, in 15 patients) who had confirmed primary malignancies (lung cancer in 23 patients, lymphoma in 2, esophageal cancer in 2, hypopharyngeal cancer in 1, prostate cancer in 1, and 1 patient in whom lesions were detected at cancer screening). All patients underwent PET/CT at 1 h post FDG injection. Diagnosis of adrenal malignant lesions was based on interval growth or reduction after chemotherapy. An adrenal mass that remained unchanged for over 1 year was the standard used to diagnose adrenal benign lesions. Values of FDG uptake and CT attenuation were measured by placing volumetric regions of interest over PET/CT images. Adrenal uptake of SUVmax ≥ 2.5 was considered to indicate a malignant lesion; SUVmax < 2.5 was considered to indicate a benign lesion. In further analysis, 1.8 was employed as the threshold for the T/L SUVmax ratio. Unenhanced CT obtained from PET/CT data was considered positive for adrenal malignant lesions based on a CT attenuation value ≥ 10 HU; lesions with a value < 10 HU were considered adrenal benign lesions. Mann–Whitney’s U test was used for statistical analyses.

Results

SUVmax in adrenal malignant lesions (7.4 ± 3.5) was higher than that in adrenal benign lesions (2.1 ± 0.5, p < 0.05). The CT attenuation value of adrenal malignant lesions (27.6 ± 11.9 HU) was higher than that of adrenal benign lesions (10.1 ± 12.3 HU, p < 0.05). In differentiating between adrenal benign and malignant lesions, a CT threshold of 10 HU corresponded to a sensitivity of 57%, specificity of 94%, accuracy of 74%, positive predictive value of 92% and negative predictive value of 65%. An SUVmax cut-off value of 2.5 corresponded to a sensitivity of 89%, specificity of 94%, accuracy of 91%, positive predictive value of 94% and negative predictive value of 88%. The T/L SUVmax ratio was 1.0 ± 0.2 for adrenal benign lesions and 4.5 ± 3.0 for adrenal malignant lesions. And T/L SUVmax ratio cut-off value of 1.8 corresponded to a sensitivity of 85%, specificity of 100%, accuracy of 91%, positive predictive value of 100% and negative predictive value of 83%.

Conclusions

FDG-PET/CT with additional SUVmax analysis improves the diagnostic accuracy of adrenal lesions in cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Inan N, Arslan A, Akansel G, Anik Y, Balci NC, Demirci A. Dynamic contrast enhanced MRI in the differential diagnosis of adrenal adenomas and malignant adrenal masses. Eur J Radiol. 2008;65:154–62.

    Article  PubMed  Google Scholar 

  2. Tsushima Y, Ishizaka H, Matsumoto M. Adrenal masses: differentiation with chemical shift, fast low-angle shot MR imaging. Radiology. 1993;186:705–9.

    PubMed  CAS  Google Scholar 

  3. Miyake H, Takaki H, Matsumoto S, Yoshida S, Maeda T, Mori H. Adrenal nonhyperfunctioning adenoma and nonadenoma: CT attenuation value as discriminative index. Abdom Imaging. 1995;20:559–62.

    Article  PubMed  CAS  Google Scholar 

  4. McNicholas MM, Lee MJ, Mayo-Smith WW, Hahn PF, Boland GW, Mueller PR. An imaging algorithm for the differential diagnosis of adrenal adenomas and metastases. AJR Am J Roentgenol. 1995;165:1453–9.

    PubMed  CAS  Google Scholar 

  5. Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol. 1998;171:201–4.

    PubMed  CAS  Google Scholar 

  6. Korobkin M, Brodeur FJ, Francis IR, Quint LE, Dunnick NR, Londy F. CT time-attenuation washout curves of adrenal adenomas and nonadenomas. AJR Am J Roentgenol. 1998;170:747–52.

    PubMed  CAS  Google Scholar 

  7. Hamrahian AH, Ioachimescu AG, Remer EM, Motta-Ramirez G, Bogabathina H, Levin HS, et al. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab. 2005;90:871–7.

    Article  PubMed  CAS  Google Scholar 

  8. Lee MJ, Hahn PF, Papanicolaou N, Egglin TK, Saini S, Mueller PR, et al. Benign and malignant adrenal masses: CT distinction with attenuation coefficients, size, and observer analysis. Radiology. 1991;179:415–8.

    PubMed  CAS  Google Scholar 

  9. Park BK, Kim CK, Kim B, Choi JY. Comparison of delayed enhanced CT and 18F-FDG PET/CT in the evaluation of adrenal masses in oncology patients. J Comput Assist Tomogr. 2007;31:550–6.

    Article  PubMed  Google Scholar 

  10. Park BK, Kim CK, Kim B, Lee JH. Comparison of delayed enhanced CT and chemical shift MR for evaluating hyperattenuating incidental adrenal masses. Radiology. 2007;243:760–5.

    Article  PubMed  Google Scholar 

  11. Korobkin M, Brodeur FJ, Francis IR, Quint LE, Dunnick NR, Goodsitt M. Delayed enhanced CT for differentiation of benign from malignant adrenal masses. Radiology. 1996;200:737–42.

    PubMed  CAS  Google Scholar 

  12. Caoili EM, Korobkin M, Francis IR, Cohan RH, Platt JF, Dunnick NR, et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology. 2002;222:629–33.

    Article  PubMed  Google Scholar 

  13. Tessonnier L, Sebag F, Palazzo FF, Colavolpe C, De Micco C, Mancini J, et al. Does (18)F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours? Eur J Nucl Med Mol Imaging. 2008;35:2018–25.

    Article  PubMed  CAS  Google Scholar 

  14. Beck JR. Likelihood ratios. Another enhancement of sensitivity and specificity. Arch Pathol Lab Med. 1986;110:685–6.

    PubMed  CAS  Google Scholar 

  15. Caoili EM, Korobkin M, Brown RK, Mackie G, Shulkin BL. Differentiating adrenal adenomas from nonadenomas using (18)F-FDG PET/CT: quantitative and qualitative evaluation. Acad Radiol. 2007;14:468–75.

    Article  PubMed  Google Scholar 

  16. Yun M, Kim W, Alnafisi N, Lacorte L, Jang S, Alavi A. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med. 2001;42:1795–9.

    PubMed  CAS  Google Scholar 

  17. Jana S, Zhang T, Milstein DM, Isasi CR, Blaufox MD. FDG-PET and CT characterization of adrenal lesions in cancer patients. Eur J Nucl Med Mol Imaging. 2006;33:29–35.

    Article  PubMed  Google Scholar 

  18. Gupta NC, Graeber GM, Tamim WJ, Rogers JS, Irisari L, Bishop HA. Clinical utility of PET-FDG imaging in differentiation of benign from malignant adrenal masses in lung cancer. Clin Lung Cancer. 2001;3:59–64.

    Article  PubMed  CAS  Google Scholar 

  19. Lowe VJ, DeLong DM, Hoffman JM, Coleman RE. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med. 1995;36:883–7.

    PubMed  CAS  Google Scholar 

  20. Boerner AR, Weckesser M, Herzog H, Schmitz T, Audretsch W, Nitz U, et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med. 1999;26:226–30.

    Article  PubMed  CAS  Google Scholar 

  21. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, et al. Delayed (18)F-fluoro-2-deoxy-d-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer. 2000;89:2547–54.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Atsushi Kubo of Department of Radiology in Keio University school of Medicine for the advice of this manuscript.

Author information

Authors and Affiliations

  1. Department of Radiology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan

    Masahiro Okada, Taro Shimono, Yoshihiro Komeya, Rina Ando, Yuki Kagawa, Takashi Katsube, Masatomo Kuwabara, Yukinobu Yagyu, Seishi Kumano, Izumi Imaoka, Norio Tsuchiya, Ryuichiro Ashikaga, Makoto Hosono & Takamichi Murakami

Authors
  1. Masahiro Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taro Shimono
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoshihiro Komeya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rina Ando
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuki Kagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takashi Katsube
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masatomo Kuwabara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yukinobu Yagyu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Seishi Kumano
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Izumi Imaoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Norio Tsuchiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ryuichiro Ashikaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Makoto Hosono
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Takamichi Murakami
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takamichi Murakami.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Okada, M., Shimono, T., Komeya, Y. et al. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions. Ann Nucl Med 23, 349–354 (2009). https://doi.org/10.1007/s12149-009-0246-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-009-0246-4

Keywords

Search

Navigation